Gefitinib – Revolutionizing Lung Cancer Treatment

[daisymiller 0]

Gefitinib is a groundbreaking targeted therapy used primarily for non-small cell lung cancer (NSCLC). As an EGFR (epidermal growth factor receptor) inhibitor, it works by blocking cancer cell growth, making it a preferred treatment for patients with EGFR mutations. Unlike traditional chemotherapy, Gefitinib specifically targets cancer cells, reducing side effects and improving patient outcomes.

With its increasing demand, Gefitinib manufacturer play a crucial role in ensuring global accessibility to this life-saving drug. Countries like India and China are major suppliers, making affordable treatment available worldwide. Ongoing research continues to expand Gefitinib’s potential, offering new hope to lung cancer patients.